Company Announcements

Director Dealings

Source: RNS
RNS Number : 0193S
Allergy Therapeutics PLC
11 November 2021



Allergy Therapeutics plc


("Allergy Therapeutics" or the "Company")


Director Dealings


11 November 2021 - Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that Peter Jensen, Non-Executive Chairman, has purchased 30,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 36 pence per Ordinary Share. Following the transaction, the total beneficial interest of Peter Jensen is 300,000 Ordinary Shares, representing 0.05% of the of the issued share capital of the Company to which voting rights are attached.


For further information, please contact:


Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer


Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking


Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott, David Daley, Davide Salvi, Alex Gunter



Notes for editors:


About Allergy Therapeutics


Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.


Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see




Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:



Details of the person discharging managerial responsibilities/person closely associated




Peter Jensen


Reason for the notification




Non-Executive Chairman, Director


Initial notification/Amendment


Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Allergy Therapeutics plc





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument


Identification code

0.1p ordinary shares





Nature of the transaction


Purchase of Ordinary Shares


Price(s) and volume(s)



Price(s) per Ordinary Share


36 pence




Aggregated information






Date of the transaction


10 November 2021


Place of the transaction



London Stock Exchange - AIM






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.